Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

82.90 -3.72 (-4.29%)
Streaming Delayed Price Updated: 12:47 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MiNK Therapeutics (NASDAQ:INKT) shares rose 16.88% to $16.96 during Friday's regular session. Vocera Communications (NYSE:VCRA) shares increased by 12.13% to $... 
Via Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Lemaitre Vascular Inc (LMAT) Q3 2021 Earnings Call Transcript
LMAT earnings call for the period ending August 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ: 
Via Benzinga
Earnings Scheduled For April 29, 2021
Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •... 
Via Benzinga
Recap: LeMaitre Vascular Q3 Earnings
LeMaitre Vascular (NASDAQ:LMAT) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021
Upgrades For Signet Jewelers Ltd (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Is This Under-the-Radar Medical Device Company a Post-Earnings Buy?
LeMaitre Vascular's operating fundamentals and balance sheet suggest it's a buy, depending on your objectives. 
Via The Motley Fool
Lemaitre Vascular Inc (LMAT) Q2 2021 Earnings Call Transcript
LMAT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
55 Biggest Movers From Yesterday
Gainers SGOCO Group, Ltd. (NASDAQ: SGOC) shares gained 37.6% to settle at $13.20 on Wednesday. SGOCO Group regained compliance with Nasdaq's listing standards on July 12 by... 
Via Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
Gainers Datasea Inc. (NASDAQ: DTSS) climbed 85% to $5.42. Datasea’s subsidiary Shuhai Zhangxun Information Technology Co., Ltd inked six purchase and distribution... 
Via Benzinga
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical... 
Via Benzinga
LeMaitre Vascular Sees Better Than Expected Q2 Sales, Raises $55M Via Equity At 9% Discount
LeMaitre Vascular Inc (NASDAQ: LMAT) has announced preliminary Q2 2021 results and sees net sales of $40.7 million compared to an estimated $37.9 million, up 64%Y/... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers scPharmaceuticals (NASDAQ:SCPH) ... 
Via Benzinga
Should Investors Consider This Expanding Healthcare Business After Its Massive Dividend Hike?
Did LeMaitre Vascular jeopardize its payout with its recent 16% dividend lift? 
Via The Motley Fool
Glaukos Stock Sees Its Relative Strength Rating Improve To Key Above-80 Level
Glaukos stock had its Relative Strength (RS) Rating upgraded from 78 to 81 Thursday. Is Glaukos on your watchlist? 
Via Investor's Business Daily
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Highs On Monday
Monday's morning session saw 49 companies set new 52-week highs. Intriguing Points: The largest company by market cap to hit a new 52-week high was Shopify (... 
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
Edwards Lifesciences Stock Gets Revived With Relative Strength Rating Upgrade
The Relative Strength (RS) Rating for Edwards Lifesciences stock headed into a higher percentile Tuesday, as it got a lift from 67 to 71. 
Via Investor's Business Daily
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Analyzing LeMaitre Vascular's Ex-Dividend Date
LeMaitre Vascular (NASDAQ:LMAT) declared a dividend payable on June 3, 2021 to its shareholders as of April 27, 2021. It was also announced that shareholders of LeMaitre Vascular'... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 30.17% to $1.42 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of... 
Via Benzinga
LeMaitre Vascular inc (LMAT) Q1 2021 Earnings Call Transcript
LMAT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: LeMaitre Vascular Q1 Earnings
Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 75.00% over the past... 
Via Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.